Why the study?
Does percutaneous balloon mitral valvuloplasty alter ANP and BNP levels in patients with rheumatic mitral stenosis?
Does percutaneous balloon mitral valvuloplasty alter ANP and BNP levels in patients with rheumatic mitral stenosis?
Baseline NYHA class is associated with clinical outcomes in patients with rheumatic mitral stenosis undergoing percutaneous balloon mitral valvuloplasty.
Natriuretic peptide changes post-PBMV associate with endpoints; leaves open clinical utility pending prospective validation.
INTRODUCTION: Atrial (ANP) and B-type (BNP) natriuretic peptides are hormones secreted by the heart as a response to volume expansion and pressure overload. AIM: To assess the changes of ANP and BNP after percutaneous balloon mitral valvuloplasty (PBMV) and to investigate factors associated with endpoints. MATERIAL AND METHODS: , mean mitral gradient (MMG) 8.2 (7.1-9.2) mm Hg, NYHA 2.09 (1.9-2.5)). Patients were followed up for 29.1 months for the search of endpoints. RESULTS: = 0.022). CONCLUSIONS: Patients with MS had increased levels of both BNP and ANP. Baseline NYHA class was found to be associated with outcomes after the procedure.
No takes yet. Share an insight, caveat, or question.
Mazurkiewicz et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: